CRISPR Therapeutics reported a mixed but mobilizing third quarter: the first CRISPR-based therapy continues to scale globally. At the same time, the company pushes deeper into in vivo editing and autoimmune CAR-T. Casgevy, co-commercialized with Vertex, added momentum with reimbursement secured in Italy, nearly 300 referrals to authorized treatment centers, 165 first cell collections, and 39 infusions to date across regions. Pediatric development is advancing, with enrollment complete in two global phase 3 studies in children aged 5 to 11, and initial data slated for presentation at the ASH annual meeting. Beyond hemoglobinopathies, CRISPR unveiled positive phase 1 results for CTX310. This ANGPTL3 liver-editing candidate lowered triglycerides and LDL after a single IV course, and flagged a mid-2026 first-in-human start for CTX460, the lead asset from its new Syntase precision-editing platform. The company also dosed the first patient in a phase 2 trial of SRSd107, a long-acting Factor XI siRNA co-developed with Sirius Therapeutics, and expects broad year-end updates for CTX112, its allogeneic CD19 CAR-T for autoimmune disease and B-cell malignancies. Cash and securities totaled about $1.9 billion at quarter-end. Vertex, the program lead and manufacturer for Casgevy, signaled more than $100 million in 2025 revenue with a larger step-up in 2026.
The strategic question is whether CRISPR can convert scientific breadth into durable commercial leverage while its flagship therapy is still navigating real-world adoption. The patient journey for an ex vivo gene-edited cell therapy is complex, and capacity at authorized treatment centers remains a gating factor. The company’s P&L shows the near-term drag of shared commercialization costs, even as revenue accrues to its partner. Yet the pipeline pivot is notable: cardiometabolic in vivo editing, an allogeneic autoimmune franchise, and a complementary RNAi collaboration suggest a company intent on being more than a single-asset beneficiary.
For patients and HCPs, the pediatric readout and maturing post-approval experience are pivotal. Earlier intervention in sickle cell disease and beta thalassemia could reshape lifetime outcomes, but it raises fresh considerations around long-term durability, monitoring, and informed consent in younger populations. For payers, Italy’s agreement underscores the reimbursement chessboard now extending beyond the U.S. and northern Europe into larger thalassemia markets. Outcomes tracking, ATC throughput, and standardized care pathways will determine whether one-time therapies are budgetable at scale and whether milestone-based arrangements gain traction.
Competition is intensifying, with CRISPR pushing next. In vivo cardiometabolic editing is moving from concept to clinic alongside base editing and increasingly potent siRNA and antisense approaches targeting Lp(a), PCSK9, and ANGPTL3. One-and-done editing could be commercially disruptive if safety and dose control hold up against chronic RNA therapies. In autoimmune disease, allogeneic CD19 CAR-T is emerging as a solution to the logistical and cost challenges of autologous products, but clinical consistency and manufacturing reliability must be demonstrated. The Factor XI program arrives as oral FXIa inhibitors face mixed outcomes; a semi-annual injectable that cleanly separates antithrombotic efficacy from bleeding risk would have broad appeal across surgical and chronic settings.
Near-term, watch three levers: pediatric ASH data as a catalyst for demand and payer decisions; the shape of CTX310’s next studies as a signal of confidence in durable lipid editing; and the year-end CTX112 update to gauge how quickly allogeneic CAR-T can move from promise to platform. The bigger test is execution: can CRISPR translate a diversified modality stack and a deep cash position into scaled access, predictable manufacturing, and payer-aligned value, before competitors normalize gene editing as just another tool in the cardiovascular and autoimmune armamentarium?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment